| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -32.4 | -20.3 |
| EPS (diluted, $ a share) | $-0.72 | $-0.46 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SION. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sionna Therapeutics, Inc.: key numbers
- Share price
- $3.12Close, Nov 16
- Market cap
- $141M
- Shares outstanding
- 45.24MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sionna Therapeutics, Inc.
All →Sionna Therapeutics Financial Results
Sionna Therapeutics reported Q3 2026 financial results and announced plans to initiate the AscenSION CF Phase 2 proof-of-concept trial for its SION-451 and SION-2222 dual combination in Q1 2027. The company ended the quarter with $249.8 million in cash, which is expected to fund operations into the second half of 2029.
- Term
- Q3 2026
“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination. We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”
Mike Cloonan, President and Chief Executive Officer
Sionna Therapeutics Director Ra Capital Management L.P. Sells $21.8M of Stock
Ra Capital Management L.P., Director, sold 3,448,811 shares of Sionna Therapeutics, Inc. at $6.32 to $7.46 a share (average $6.33) in 2 transactions, worth $21.8M in total on Sep 17, 2026. Shares held after the trade: 3,448,812 (-1.0%).
- Value
- $21.8M
- Shares
- 3,448,811
- Average price
- $6.33
- Role
- Director
- Holding change
- -1.0%
- Trade date
- Sep 17, 2026
Sionna Therapeutics Other 8-K Filing
Sionna Therapeutics approved a restructuring plan to focus resources on its SION-451 and SION-2222 dual combination program, involving a 46% workforce reduction and the wind-down of its SION-719 add-on program. The company expects to incur approximately $6.4 million in restructuring charges, primarily for severance and contract close-out costs, while extending its cash runway into the second half of 2029. Additionally, Chief Business Officer Caroline Stark Beer was terminated without cause as part of the reorganization.
- Earnings call
- Sep 14, 2026, 4:30 PM ET